Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics

Código QR

Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics

Scott A McConnell,1 Dharmik N Desai,1 Sejal P Faldu,1 Marjie L Hard,2 Angela Y Wehr,3 Peter J Weiden,1 Lisa von Moltke3 1Medical Affairs, Alkermes, Inc., Waltham, MA, 2Nuventra Pharma Sciences, Durham, NC, 3Clinical Research, Alkermes, Inc., Waltham, MA, USAThe recent publication by Salzman et al1...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	McConnell SA, Desai DN, Faldu SP, Hard ML, Wehr AY, Weiden PJ, von Moltke L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	aripiprazole aripiprazole lauroxil pharmacokinetics;long-acting injectables Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/8036fa34f015403b9c1b841a7c733a17
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
por: Citrome L, et al.
Publicado: (2019)

Aripiprazole en el tratamiento sintomático del síndrome de Gilíes de la Tourette (enfermedad de los tics)
por: Miranda C,Marcelo, et al.
Publicado: (2007)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Chih-Sung Liang, et al.
Publicado: (2021)

Aripiprazole for late-life schizophrenia
por: Jeffrey Rado, et al.
Publicado: (2010)

DEVELOPMENT OF A SIMPLE AND SPECIFIC UHPLC ASSAY FOR THE DETERMINATION OF ARIPIPRAZOLE AND DEHYDROARDPDPRAZOLE IN RAT PLASMA
por: YENICELI UĞUR,DUYGU, et al.
Publicado: (2015)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such P, et al.
Publicado: (2021)

Management of psychosis in patients with Alzheimer’s disease: focus on aripiprazole
por: Subramanian Madhusoodanan, et al.
Publicado: (2008)

The Binding of Aripiprazole to Plasma Proteins in Chronic Renal Failure Patients
por: Kenshiro Hirata, et al.
Publicado: (2021)

Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies
por: Madera JJ, et al.
Publicado: (2019)

Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole
por: Salzman PM, et al.
Publicado: (2017)

Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole
por: Peters-Strickland T, et al.
Publicado: (2016)

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies
por: Peters-Strickland T, et al.
Publicado: (2019)

Aripiprazole combination for reversal of paliperidone-induced increase in prolactin level
por: Zhi P, et al.
Publicado: (2018)

Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment
por: Madera J, et al.
Publicado: (2019)

Severe arrhythmia induced by orally disintegrating aripiprazole tablets (Bosiqing®): a case report
por: Shao Q, et al.
Publicado: (2015)

Optimization of Processing Parameters of Nanoemulsion Containing Aripiprazole Using Response Surface Methodology
por: Samiun WS, et al.
Publicado: (2020)

Low-dose aripiprazole for refractory burning mouth syndrome
por: Umezaki Y, et al.
Publicado: (2016)

Aripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: a case series
por: Sugawara Kikuchi Y, et al.
Publicado: (2019)

A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression
por: Sugawara H, et al.
Publicado: (2016)

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
por: Kishi T, et al.
Publicado: (2016)

Comparación del efecto de la terapia prolongada con antipsicóticos atípicos o convencionales en la incidencia de diabetes mellitus 2: Revisión sistemática y metaanálisis
por: Sapunar Z,Jorge, et al.
Publicado: (2009)

Effect of amisulpride, olanzapine, quetiapine, and aripiprazole single administration on c-Fos expression in vasopressinergic and oxytocinergic neurons of the rat hypothalamic supraoptic nucleus
por: Kiss Alexander, et al.
Publicado: (2020)

Aripiprazole augmentation in managing comorbid obsessive–compulsive disorder and bipolar disorder: a case with suicidal attempts
por: Lai J, et al.
Publicado: (2016)

Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials
por: Luan SX, et al.
Publicado: (2018)

c-Fos and FosB/ΔFosB colocalizations in selected forebrain structures after olanzapine, amisulpride, aripiprazole, and quetiapine single administration in rats preconditioned by two different mild stressors sequences
por: Kiss Alexander, et al.
Publicado: (2020)

Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome: an open-labeled clinical observation
por: Omori Y, et al.
Publicado: (2018)

Spatial relationship between the c-Fos distribution and enkephalinergic, substance P, and tyrosine hydroxylase innervation fields after acute treatment with neuroleptics olanzapine, amisulpride, quetiapine, and aripiprazole in the rat septum
por: Kiss Alexander, et al.
Publicado: (2019)

Haloperidol and aripiprazole impact on the BDNF and glucocorticoid receptor levels in the rat hippocampus and prefrontal cortex: effect of the chronic mild stress
por: Osacka Jana, et al.
Publicado: (2021)

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
por: Cuomo I, et al.
Publicado: (2018)

COMT Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia
por: Kaneko H, et al.
Publicado: (2018)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
por: Di Lorenzo R, et al.
Publicado: (2019)

Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center, Retrospective Case Series
por: Alsayouf HA, et al.
Publicado: (2020)

Effect of aripiprazole on non-24-hour sleep–wake rhythm disorder comorbid with major depressive disorder: a case report
por: Matsui K, et al.
Publicado: (2017)

Early antipsychotic treatment in juvenile rats elicits long-term alterations to the adult serotonin receptors
por: De Santis M, et al.
Publicado: (2018)

Atypical antipsychotics as add-on treatment in late-life depression
por: Cakir S, et al.
Publicado: (2016)

c-Fos expression in the hypothalamic paraventricular nucleus after a single treatment with a typical haloperidol and nine atypical antipsychotics: a pilot study
por: Kiss Alexander
Publicado: (2018)

Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice
por: Roganović Maša, et al.
Publicado: (2021)

Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion
por: Veselinović T, et al.
Publicado: (2018)

A pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy
por: Gellért Balázs Karvaly, et al.
Publicado: (2021)

A generic 89Zr labeling method to quantify the in vivo pharmacokinetics of liposomal nanoparticles with positron emission tomography
por: Li N, et al.
Publicado: (2017)